# NCT01639508 (NCT01639508)

> Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01639508
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Cabozantinib
- Enrollment: 86
- Primary outcome: objective response rate (ORR) (Group A)
- Primary outcome: objective response rate (ORR) (Group B)

## Indexed commentary on NCT01639508 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01639508